GENELABS TECHNOLOGIES INC /CA 4
4 · GENELABS TECHNOLOGIES INC /CA · Filed Jan 9, 2009
Insider Transaction Report
Form 4
MORGAN STANLEY
10% Owner
Transactions
- Sale
Common Stock
2009-01-07$1.30/sh−5,374,343$6,986,646→ 0 total(indirect: By Subsidiary)
Footnotes (2)
- [F1]The reported securities are held directly by certain funds (each, a "Fund" and collectively, the "Funds") managed by indirect subsidiary entities of the reporting person. FrontPoint Partners LLC ("FPP"), an indirect wholly owned subsidiary of the reporting person is the parent company of each entity that is the investment manager of one or more of the Funds. This form is filed without prejudice to the reporting person's position that none of the Funds nor FPP or any of its subsidiaries, nor the reporting person, individually or in aggregate, are required to file beneficial ownership reports under Section 16(a) of the a Securities Exchange Act of 1934, and should not be construed or interpreted as a concession or admission that such reports are required.
- [F2]The completion of the tender offer by Gemstone Acquisition Corporation ("Purchaser"), a wholly-owned subsidiary of SmithKline Beecham Corporation and a wholly-owned subsidiary of GlaxoSmithKline PLC, contemplated by the Agreement and Plan of Merger (the "Merger Agreement), dated as of October 29, 2008, occurred on January 6, 2009. Each share of common stock, no par value, of the Issuer held by the Reporting Person was accepted for payment by the Purchaser at a price of $1.30 per share, on January 7, 2009.